Fig. 2

Vagotomy does not influence LSCs expansion at the early phase of LPS-induced lung injury. a Schematic model of vagotomy and LPS administration. We cut the right vagal nerves, and then, PBS or LPS was intratracheally delivered. b A scheme shows the time of the interventional measures in the model. Mice were vagotomized 5 days before LPS challenge. PBS or LPS (5 mg/kg) was intratracheally delivered to sham or vagotomized mice and was followed up for 1 or 3 days. c The gating strategy of LSCs (Sca1⁺CD45⁻CD31⁻), Ki67⁺ LSCs, Ki67⁺ cells, cell viability of LSCs (measured by the fixable viability stain 780 reagent) and their changes in sham or vagotomized mice treated either with PBS or LPS (5 mg/kg) for 1 day. d–g Changes in LSCs (d), Ki67⁺ LSCs (e), Ki67⁺ cells (f), and cell viability of LSCs (g) in sham or vagotomized mice treated either with PBS or LPS (5 mg/kg) for 1 day. h–k Changes are shown in the numbers of LSCs (h), Ki67⁺ LSCs (i), and Ki67⁺ cells (j), and cell viability of LSCs (k) in sham or vagotomized mice treated either with PBS or LPS (5 mg/kg) for 3 days. N = 3–4 in each group. Data are presented as the mean ± SD. *P < 0.05, **P < 0.01, and ***P < 0.00, as assessed by one-way ANOVA. i.t., intratracheally; Vx, vagotomy; LPS, lipopolysaccharide